^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Excerpt:
...Acute myeloid leukemia with either Flt-3, TET-2, p53, DNMT3A, or ASXL1 mutation, mutations of genes involved in the chromatin/spliceosome category (EZH2, SRSF2, U2AF1, ZRSR2), BCOR, and RUNX1, as well as MLL rearrangement, EVI1 overexpression in complete morphologic remission; or 3....
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
Title:

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Published date:
09/21/2021
Excerpt:
Upon treatment with VEN, mutant cells demonstrated increased growth inhibition. In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA.
DOI:
10.1038/s41408-021-00541-0
Evidence Level:
Resistant: C3 – Early Trials
Title:

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Published date:
07/22/2021
Excerpt:
ASXL1DEL /ASXL1MUT patients were correlated by univariable analysis with a worse response to AZA.
DOI:
10.1111/bjh.17675